TP53 and non-small cell lung carcinoma: In this study, we observed schedule-dependent modulation of PMX cytotoxicity when combined with the HDACi MS275, which aligns with prior findings showing that HDAC inhibitors like Givinostat can reverse PMX resistance in NSCLC cell lines, regardless of p53 status52,53.